CD20/CD19 cell therapy for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is testing a new cellular therapy using immune cells (called CD20/CD19 cells) for patients with a certain type of lymphoma that has not been cured by standard treatments. The cells are designed to find and destroy your lymphoma cells, potentially helping you achieve remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and expected to live at least 3 months more.
- You must have a type of B-cell lymphoma that is positive for a marker called CD20 and has come back or not responded to treatment.
- You need to have at least one tumor that can be measured on a CT scan.
- You must have adequate bone marrow function (like enough red blood cells, white blood cells, and platelets) without transfusions in the last week.
- You must have adequate kidney, liver, and lung function.
- You must use effective birth control during the trial and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This Phase 1 study tests a new immune-cell treatment made from donated cord blood. It aims to treat people whose B-cell lymphoma has come back or did not respond, specifically when the tumor has CD19 on it.
This trial tests a new cell therapy (called RJMty19) for people with B-cell lymphoma that has returned or not responded to standard treatments. The therapy aims to find and attack cancer cells.
This early trial tests a new type of cell therapy (called ARI0003) for aggressive B-cell lymphomas that have not responded to standard treatments or have relapsed. The therapy uses your own immune cells to fight the cancer, and it may offer a new option when other treatments have not worked well.
Hear when a new R/R B-NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.